He also mentioned that my vitamin D levels were low, as well
Regulation and boundary between cosmetic, medical device and medicine In Europe, topical peptides fall under three distinct regulatory frameworks according to their claim and mechanism: Cosmetic (EC Regulation 1223/2009) Surface cutaneous action, beauty and hygiene claims No therapeutic claim authorised Product information file (PIF), safety evaluation Examples: Matrixyl, Argireline, Pal-GHK in anti-ageing serums Medical device (EU Regulation 2017/745) Main physical/mechanical action, medical claim Classes I, IIa, IIb, III according to risk CE marking mandatory, notified bodies for class IIa+ Example: GHK-Cu dressings for wound healing Medicine (Directive 2001/83/EC) Explicit therapeutic claim, pharmacological action MA mandatory (EMA or national agencies), phase I-III clinical trials Example: Afamelanotide for erythropoietic protoporphyria (MA 2014) This segmentation has direct implications for research : a molecule can change regulatory status according to its final formulation and claims
Biotin (Vitamin B7): While biotin supplementation has not been proven to reverse telogen effluvium specifically, true biotin deficiency does cause hair loss
3 , e88 (2014)
This research described MOTS-c as a mitochondrial-derived peptide that regulates insulin sensitivity and metabolic homeostasis
